[Effect of etoposide for urogenital tumors]

Ten patients with urogenital tumors were treated with Etoposide. The dose schedule was 100 mg i.v. daily for 5 days and was repeated after 4-5 weeks. One patient with ureteral tumor experienced partial remission for 60 days and minor regression was achieved in 3 patients. The major side effects were leukopenia (60%) and thrombocytopenia (40%). Mean WBC nadir of 1050/mm3 occurred at 13.5 days and recovered quickly after a further 7.5 days.